VEGFR2/CD309 antibody (AA 20-244)

Catalog No. ABIN5693262

This Rabbit Polyclonal antibody specifically detects VEGFR2/CD309 in WB, IHC, FACS, IF and ICC. It exhibits reactivity toward Mouse and Rat. It has been mentioned in 5+ publications

Quick Overview for VEGFR2/CD309 antibody (AA 20-244) (ABIN5693262)

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Reactivity: Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This VEGFR2/CD309 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunofluorescence (IF), Immunocytochemistry (ICC)

Product Details anti-VEGFR2/CD309 Antibody

Binding Specificity: AA 20-244

Purpose: Anti-VEGF Receptor 2/Kdr Antibody

Specificity: No cross reactivity with other proteins.

Cross-Reactivity (Details): No cross-reactivity with other proteins.

Characteristics: Anti-VEGF Receptor 2/Kdr Antibody. Tested in Flow Cytometry, IF, IHC, ICC, WB applications. This antibody reacts with Mouse, Rat.

Purification: Immunogen affinity purified.

Immunogen: E. coli-derived mouse VEGF Receptor 2 recombinant protein (Position: A20-L244).

Isotype: IgG

Application Details

Application Notes: Western blot, 0.1-0.5 μg/mL Immunohistochemistry (Paraffin-embedded Section), 0.5-1 μg/mL Immunocytochemistry/Immunofluorescence, 2 μg/mL Flow Cytometry (Fixed), 1-3 μg/1x10⁶ cells

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Concentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na₂HPO₄, 0.05 mg NaN₃.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

References for anti-VEGFR2/CD309 antibody (ABIN5693262)

Huang, Li, Pan, Cheng, Ren, Jia, Ma, Xu: "A novel multi-target RNAi adenovirus inhibits hepatoma cell proliferation, migration, and induction of angiogenesis." in: Oncotarget, Vol. 7, Issue 36, pp. 57705-57713, (2018) (PubMed).

Yan-Ping, Xiao-Qin, Xiao Ping, Ying Quan: "Effects of Chronic Exposure to Sodium Arsenite on Expressions of VEGF and VEGFR2 Proteins in the Epididymis of Rats." in: BioMed research international, Vol. 2017, pp. 2597256, (2018) (PubMed).

Zhu, Tuerxun, Hui, Abliz: "Effects of propranolol and isoproterenol on infantile hemangioma endothelial cells in vitro." in: Experimental and therapeutic medicine, Vol. 8, Issue 2, pp. 647-651, (2014) (PubMed).

Liu, Yang, Zhang, Shui, Song, Yao, Dai, Sun: "Fructopyrano-(1?4)-glucopyranose inhibits the proliferation of liver cancer cells and angiogenesis in a VEGF/VEGFR dependent manner." in: International journal of clinical and experimental medicine, Vol. 7, Issue 11, pp. 3859-69, (2014) (PubMed).

Wu, You, Ma, Li, Yuan, Li, Ye, Liu, Yao, Chen, Lai, Yang: "Role of transient receptor potential ion channels and evoked levels of neuropeptides in a formaldehyde-induced model of asthma in BALB/c mice." in: PLoS ONE, Vol. 8, Issue 5, pp. e62827, (2013) (PubMed).

Target Details for VEGFR2/CD309

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Alternative Name: Kdr

Background:

Background: KDR (Kinase Insert Domain Receptor), also known as FLK1, VEGFR or VEGFR2, is a VEGF receptor. KDR is the human gene encoding it. Vascular endothelial growth factor (VEGF) is the only mitogen that specifically acts on endothelial cells. Its expression is upregulated by hypoxia, and its cell-surface receptor, known as fetal liver kinase-1 (Flk1) in mouse, is exclusively expressed in endothelial cells. Flk1 is the mouse homolog of KDR.

Gene Full Name: kinase insert domain protein receptor

Molecular Weight: 150 kDa

Gene ID: 16542

UniProt: P35918

Pathways: RTK Signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling